CJC-1295
Quick facts
- Researched for
- Growth-hormone support, deeper sleep, recovery, body composition and joint comfort
- Route or form
- Injection
- Evidence so far
- One small human study, reports, a talk, and a trial that stopped after a death.
- Not established
- Results from one form, DAC or no-DAC, do not prove what the other does.
- Commonly researched
- 100 mcg, once dailyPractitionerSee every range
- Where to get it
- No product link here.See why in Next step
By the Learn Peptides editorial team · Updated · How We Research
What people are researching it for
People are researching CJC-1295 no DAC for growth-hormone support, deeper sleep, recovery, body composition, and joint comfort.
Reasons people look into CJC-1295. An interest is not a promise that it works.
- Injury & recovery
- Body composition & performance
- Sleep
- Skin, hair & tanning
People often describe deeper sleep first, then slower changes in body, joints or skin.
Community reports
People often describe deeper sleep or better recovery before noticing slower changes in body composition, joints, or skin. It is commonly researched with Ipamorelin.
Community reports
People take CJC-1295 (most often the shorter-acting no-DAC form, sometimes the longer-acting DAC version) alongside a GHRP like ipamorelin, mainly hoping for deeper sleep, faster injury recovery, and better skin. The two forms are frequently sold and discussed as if they were the same drug, even though people report different downsides for each.
Human studies show drugs like it raise growth hormone; much CJC-1295 research used DAC.
Human studies of growth-hormone-releasing compounds show they can raise . Much of the published CJC-1295 research, however, used a DAC form.
A peptide that tells the pituitary gland to release more of the body's own overnight.
What this is based on
- Human researchStudied in people for this or a related question.
- Community reportsWhat people describe noticing. Not proof of cause.
- Industry perspectiveCommentary from practitioners and the industry, based on experience. Not a study.
- Learn Peptides explanationOur own plain-English summary of the sources. It is not a source itself.
Results from one form, DAC or no-DAC, do not prove what the other does.
Results from studies of the DAC form do not prove what the no-DAC form does, and the reverse is also true.
Safety notes
Tested in people. How many took part, for how long, and who they were still matter.
- You have trouble breathing or wheezing, or your face, lips, tongue or throat swell.
- You get hives away from the injection site, or feel severely dizzy or faint.
For these signs, call 911 or your local emergency number.
- Redness spreads, or heat, swelling or pain keeps growing where you injected.
- A lump keeps growing or does not go away, or you see pus or red streaks.
- You have a fever or chills, or feel sick all over.
- Avoid with active or recent cancer as a precaution, even though data doesn't clearly show it raises recurrence risk. Industry perspective
- Avoid during pregnancy or breastfeeding. Industry perspective
- The DAC version is probably not a good idea if you have diabetes or insulin resistance, since it needs close blood sugar monitoring. Industry perspective
- Severe allergy-prone people can have anaphylactic reactions and should be prepared. Industry perspective
- Banned in drug-tested sport.
- Won't work if underlying testosterone or thyroid problems are untreated. Industry perspective
- People under 25 likely won't get much benefit beyond what they're already naturally producing. Industry perspective
Shows practitioner ranges for the no-DAC and DAC forms, each with its source.
Commonly researched ranges, and how they were measured.
Commonly researched range for CJC-1295
100 mcg
once daily · Injection
Practitioner
All 6 ranges in our record
Each one is labeled with where it comes from. They are different ways of using CJC-1295, not steps to follow in order.
Standard, no-DAC general optimization (the practitioner's default)
Practitioner- Amount per dose
- 100 mcg
- How often
- Once daily. Before bed.
- Typical schedule
- 12-16 weeks on, 4-6 weeks off; or 5 days on, 2 days off
- Route
- Injection
No-DAC performance and stacking (tier 2)
Practitioner- Amount per dose
- 100 mcg
- How often
- Twice daily. Before bed, plus pre- or post-training or first thing in the morning.
- Typical schedule
- Not stated
- Route
- Injection
No-DAC significant dysfunction / injury recovery (tier 3)
Practitioner- Amount per dose
- 100 to 200 mcg
- How often
- Two to three times per day
- Typical schedule
- Not stated
- Route
- Injection
No-DAC, longevity
Practitioner- Amount per dose
- 100 mcg
- How often
- Five to seven nights a week
- Typical schedule
- 12-16 weeks
- Route
- Injection
No-DAC, skin and connective tissue
Practitioner- Amount per dose
- 100 mcg
- How often
- Nightly, continuously. Before bed.
- Typical schedule
- 16+ weeks
- Route
- Injection
DAC form (non-default, only if experimenting)
Practitioner- Amount per dose
- 1,000 to 2,000 mcg
- How often
- Once weekly (some split into two injections every 3-4 days)
- Typical schedule
- Not stated
- Route
- Injection
These ranges were last reviewed Sep 2026.
Check your syringe math with your own numbers.
A peptide that acts on the gland that releases growth hormone, usually with Ipamorelin.
CJC-1295 works on the pituitary gland, the small gland at the base of the brain that governs release. It's discussed as the anchor of many body-composition and longevity because it works while you sleep, which is when the body already does most of its fat-burning and repair work. It's almost always discussed alongside Ipamorelin.
Next step
No partner product
We have no US Precision Peptides listing for CJC-1295, so there is no product link. That says nothing about the research.
About product links
Purchases at US Precision Peptides help keep Learn Peptides free.